Abstract
Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 87-91 |
| Number of pages | 5 |
| Journal | Biotherapy |
| Volume | 23 |
| Issue number | 2 |
| Publication status | Published - 2009 Mar |
| Externally published | Yes |
Fingerprint
Keywords
- Biomarker
- CEA
- Lung cancer
- Tumor marker
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Biomarkers in lung cancer : Present status and future perspective -what is a useful biomarker for lung cancer? / Asamura, Hisao.
In: Biotherapy, Vol. 23, No. 2, 03.2009, p. 87-91.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biomarkers in lung cancer
T2 - Present status and future perspective -what is a useful biomarker for lung cancer?
AU - Asamura, Hisao
PY - 2009/3
Y1 - 2009/3
N2 - Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.
AB - Biomarkers have been defined as having a characteristic that is objectively measurable and evaluable as an indicator of normal biologic processes, pathogenic process, or pharmacologic response to a therapeutic intervention. In most instances, they are proteins or their fragments, DNA and RNA, low molecular compounds. In lung cancer, molecular markers are expected to play roles in early detection and screening, in anticipation of a therapeutic response and outcome (prognosis), and the safety of the treatment. Future clinical trials are closely associated with the prognosis and response to the treatment.
KW - Biomarker
KW - CEA
KW - Lung cancer
KW - Tumor marker
UR - http://www.scopus.com/inward/record.url?scp=64849098474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=64849098474&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:64849098474
VL - 23
SP - 87
EP - 91
JO - Biotherapy
JF - Biotherapy
SN - 0914-2223
IS - 2
ER -